PHAT shareholders elect two directors, ratify EY, approve say-on-pay at annual meeting

Phathom Pharmaceuticals, Inc.

Heidi Kunz elected Class III director with 34,023,182 for, 451,384 withheld; James Topper with 26,884,171 for, 7,590,395 withheld.
Ernst & Young LLP ratified as auditor for fiscal 2025: 51,670,346 for, 177,785 against, 53,817 abstentions.
Say-on-pay approved on non-binding advisory basis: 24,584,781 for, 8,704,739 against, 1,185,046 abstentions, 17,427,382 broker non-votes.
Say-on-frequency set to every 1 year with 30,665,967 votes for, 21,543 for 2 years, 2,611,188 for 3 years, 1,175,868 abstentions.
Company will hold annual advisory votes on executive compensation until next required say-on-pay vote.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.